JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

Home・Aktien・Gossamer Bio Inc

Search

Gossamer Bio Inc

Open

BrancheGesundheitswesen

0.35 -2.78

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.35

Max

0.36

Schlüsselkennzahlen
By Trading Economics
Einkommen	983K -47M
Verkäufe	505K 14M
Gewinnspanne	-342.329
Angestellte	161
EBITDA	-346K -46M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+1089.19% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	14. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-24M 82M
Vorheriger Eröffnungskurs	3.13
Vorheriger Schlusskurs	0.35

Nachrichtenstimmung

By Acuity

71%

29%

324 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

1.06 / 1.23 Unterstützung & Widerstand

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Mai 2026, 22:17 UTC

Ergebnisse

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4. Mai 2026, 23:47 UTC

Ergebnisse

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4. Mai 2026, 23:45 UTC

Ergebnisse

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4. Mai 2026, 23:45 UTC

Ergebnisse

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4. Mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4. Mai 2026, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Jim Beyer To Be Chief Executive of Combined Company

4. Mai 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4. Mai 2026, 22:42 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4. Mai 2026, 22:42 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4. Mai 2026, 22:41 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4. Mai 2026, 22:41 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4. Mai 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Shareholders to Own About 51% of Combined Company

4. Mai 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Board Unanimously Endorsed, Supported Deal

4. Mai 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Deal Unanimously Recommended by Vault Board

4. Mai 2026, 22:39 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4. Mai 2026, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Regis Resources to Acquire All Ordinary Shares in Vault

4. Mai 2026, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Regis Resources, Vault Minerals Agree to Merger of Equals

4. Mai 2026, 22:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4. Mai 2026, 22:26 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4. Mai 2026, 22:02 UTC

Ergebnisse

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4. Mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4. Mai 2026, 21:52 UTC

Ergebnisse

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4. Mai 2026, 21:50 UTC

Ergebnisse

Westpac: Some Sectors More Affected Than Others>WBC.AU

4. Mai 2026, 21:50 UTC

Ergebnisse

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4. Mai 2026, 21:49 UTC

Ergebnisse

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4. Mai 2026, 21:44 UTC

Ergebnisse

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4. Mai 2026, 21:44 UTC

Ergebnisse

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4. Mai 2026, 21:43 UTC

Ergebnisse

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4. Mai 2026, 21:41 UTC

Ergebnisse

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4. Mai 2026, 21:40 UTC

Ergebnisse

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

1089.19% Vorteil

12-Monats-Prognose

Durchschnitt 4.4 USD 1089.19%

Hoch 15 USD

Tief 0.3 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

9 ratings

3

Buy

5

Halten

1

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gossamer Bio Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.06 / 1.23Unterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Stimmung

By Acuity

324 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Andere Aktien aus dem Sektor

JNJ

Johnson and Johnson

225.83

UNH

UnitedHealth Group Inc

362.86

TMO

Thermo Fisher Scientific Inc

464.87

ISRG

Intuitive Surgical Inc

449.45

ABT

Abbott Laboratories

87.44

Live chat